ScreenerHero

ALKS Alkermes plc

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · alkermes.com
41.13USD-0.76%Mkt Cap: 6.95B $P/E: 109.07

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Irel…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.13BUSDP/E 24.9
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.68BUSDP/E 22.9
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1
HLUN-B
H. Lundbeck A/S
$6.51BUSDP/E 11.5

Key Statistics

Company
Market Cap6.95B USD
Enterprise Value7.90B USD
Revenue (TTM)1.67B USD
Gross Profit1.28B USD
Net Income (TTM)241.66M USD
Revenue/Share10.05 USD
Last Price41.13 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)109.07
P/E (Forward)23.03
PEG1.96
EV/EBITDA27.74
EV/Revenue4.74
P/S4.19
P/B3.86
EPS (TTM)0.37
EPS (Forward)1.81
52W Range
27.0049% of range55.67
52W High55.67 USD
52W Low27.00 USD
Profitability
Gross Margin86.69%
Oper. Margin15.50%
EBITDA Margin17.09%
Profit Margin16.37%
ROE13.28%
ROA9.72%
Growth
Revenue Growth27.00%
Earnings Growth-99.40%
Cash Flow & Leverage
Operating CF520.75M USD
CapEx (TTM)40.42M USD
FCF Margin9.20%
FCF Yield2.21%
Net Debt915.99M USD
Net Debt/EBITDA3.21
Balance Sheet
Debt/Equity0.04
Current Ratio2.30
Quick Ratio1.68
Book Value/Sh10.79 USD
Cash/Share3.91 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateMay 15, 2000
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)56.56 USD
Upside (mean)+37.5%
Target Range38.00 USD – 83.00 USD
38.00+37.5% to mean83.00
# Analysts18
Ownership
Shares Out.167.76M
Float155.20M
Insiders1.40%
Institutions107.45%
Short Interest
Short Ratio11.2d
Short % Float12.52%
Short % Out.9.03%
Shares Short15.16M
Short (prev mo.)14.76M
Technical
SMA 5046.53 (-11.6%)
SMA 20039.23 (+4.8%)
Beta0.27
S&P 52W Chg16.45%
Avg Vol (30d)1.96M
Avg Vol (10d)2.52M
Technical Indicators
RSI (14)37.6
MACD-1.6441
MACD Signal-1.7922
MACD Hist.+0.1481
BB Upper47.32 USD
BB Middle42.95 USD
BB Lower38.59 USD
BB Width20.33%
ATR (14)1.420 USD
Vol Ratio (20d)0.77x